NFL Biosciences SA

Paris Stock Exchange ALNFL.PA

NFL Biosciences SA EBITDA for the year ending December 31, 2023: USD -4.47 M

NFL Biosciences SA EBITDA is USD -4.47 M for the year ending December 31, 2023, a -48.74% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.
  • NFL Biosciences SA EBITDA for the year ending December 31, 2022 was USD -3.00 M, a -145.44% change year over year.
  • NFL Biosciences SA EBITDA for the year ending December 31, 2021 was USD -1.22 M, a -269.69% change year over year.
  • NFL Biosciences SA EBITDA for the year ending December 31, 2020 was USD -331.16 K, a 2.81% change year over year.
  • NFL Biosciences SA EBITDA for the year ending December 31, 2019 was USD -340.72 K.
Key data
Date EBITDA Net Income EPS (Diluted) Shares (Diluted, Weighted)
Market news
SV Wall Street
Paris Stock Exchange: ALNFL.PA

NFL Biosciences SA

CEO Dr. Ignacio Faus M.B.A., Ph.D.
IPO Date July 5, 2021
Location France
Headquarters 199 Rue Helene Boucher
Employees 4
Sector Consumers Staples
Industries
Tobacco Biotechnology Pharmaceuticals
Description

NFL Biosciences SA, a biotechnology company, develops natural addiction withdrawal solutions for smokers. Its natural drug candidate in pipeline to cure tobacco addiction include NFL-101, a tobacco extract that is in Phase III clinical trial targeting smoking addiction; NFL-201, a cannabis and tobacco extract, which is in preclinical stage; and NFL-301, a botanical extract (traditional Chinese medicine) that is in preclinical stage. The company was incorporated in 2006 and is based in Castelnau-le-Lez, France.

Similar companies

ABNX.PA

ABIONYX Pharma SA

USD 1.26

-0.99%

StockViz Staff

February 7, 2025

Any question? Send us an email